CSF2 and melanoma: In particular, talimogenelaherparepvec (T-VEC), an attenuated oncolytic herpes simplex virus type 1 (oHSV-1), armed with granulocyte-macrophage colony-stimulating factor (GM-CSF), has been approved as the first OV treatment for unresectable stage IIIB to IV melanoma [27].